Research advances in the mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in autoimmune hepatitis

Lifei WANG; Longlong LUO; Guojing XING; Lixia LU; Bin LI; Jiucong ZHANG; Xiaohui YU

doi:10.12449/JCH241027

Volume 40 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(10): 2092-2097

PDF( 1474 KB)

Research advances in the mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in autoimmune hepatitis

DOI: 10.12449/JCH241027

Lifei WANG^{1, 2},
Longlong LUO^{1, 2},
Guojing XING^{2, 3},
Lixia LU²,
Bin LI²,
Jiucong ZHANG^{2
,
,
,},
Xiaohui YU^{2
,
,
,}

1.
The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China
2.
Department of Gastroenterology，The 940 Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China
3.
Department of Gastroenterology，General Hospital of Ningxia Medical University，Yinchuan 750001，China

Research funding:

Gansu Province Science and Technology Plan Project Assignment (22YF7FA105);

Gansu Province Health Industry Scientific Research Plan Project Contract (GSWSKY2021-054);

Gansu Clinical Medical Research Center for Non-infectious Liver Diseases (21JR7RA017);

Liver Disease Diagnosis and Treatment Center, 940th Hospital Foundation, Joint Logistics Support Force (2021yxky079)

More Information

Corresponding author: ZHANG Jiucong， zhangjiucong@163.com （ORCID： 0000-0003-4006-3033）; YU Xiaohui， yuxiaohui528@126.com （ORCID： 0000-0002-8633-3281）
Received Date: 2024-01-11
Accepted Date: 2024-03-11
Published Date: 2024-10-25

Abstract

Abstract

Autoimmune hepatitis （AIH） is chronic hepatitis caused by the attack of live cells by the immune system， and at present， the pathogenesis of AIH remains unclear. Inflammasomes are important components of innate immunity and are involved in a variety of pathophysiological processes. Studies have shown that inflammatory response associated with nucleotide-binding oligomerization domain-like receptor protein 3 （NLRP3） plays an important role in the pathogenesis of AIH， which mainly mediates the release of proinflammatory factors and pyroptosis， thereby participating in the pathophysiological process of AIH. Therefore， the development and progression of AIH can be delayed by inhibiting the activation of NLRP3 inflammasomes， which provides new ideas for the prevention and treatment of AIH.
- Hepatitis， Autoimmune,
- NLR Family， Pyrin Domain-Containing 3 Protein,
- Therapeutics

FullText(HTML)

References(50)

References

[1]	FISCHER HP, GOLTZ D. Autoimmune liver diseases[J]. Pathologe, 2020, 41( 5): 444- 456. DOI: 10.1007/s00292-020-00807-7.
[2]	SHIFFMAN ML. Autoimmune hepatitis: Epidemiology, subtypes, and presentation[J]. Clin Liver Dis, 2024, 28( 1): 1- 14. DOI: 10.1016/j.cld.2023.06.002.
[3]	MURATORI L, LOHSE AW, LENZI M. Diagnosis and management of autoimmune hepatitis[J]. BMJ, 2023, 380: e070201. DOI: 10.1136/bmj-2022-070201.
[4]	KOMORI A. Recent updates on the management of autoimmune hepatitis[J]. Clin Mol Hepatol, 2021, 27( 1): 58- 69. DOI: 10.3350/cmh.2020.0189.
[5]	PAPE S, SNIJDERS RJALM, GEVERS TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group[J]. J Hepatol, 2022, 76( 4): 841- 849. DOI: 10.1016/j.jhep.2021.12.041.
[6]	LU Y, SUN FF, ZENG Z, et al. Research advances on autoimmune hepatitis[J/CD]. Chin J Liver Dis(Electronic Version), 2022, 14( 4): 1- 9. DOI: 10.3969/j.issn.1674-7380.2022.04.001. 路遥, 孙芳芳, 曾湛, 等. 自身免疫性肝炎研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 4): 1- 9. DOI: 10.3969/j.issn.1674-7380.2022.04.001.
[7]	LI Z, GUO JL, BI LQ. Role of the NLRP3 inflammasome in autoimmune diseases[J]. Biomed Pharmacother, 2020, 130: 110542. DOI: 10.1016/j.biopha.2020.110542.
[8]	RUMPRET M, von RICHTHOFEN HJ, PEPERZAK V, et al. Inhibitory pattern recognition receptors[J]. J Exp Med, 2022, 219( 1): e20211463. DOI: 10.1084/jem.20211463.
[9]	LEU SY, TSANG YL, HO LC, et al. NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners[J]. J Endocrinol, 2023, 257( 2): e220184. DOI: 10.1530/JOE-22-0184.
[10]	SCHMIDT FI, LU A, CHEN JW, et al. A single domain antibody fragment that recognizes the adaptor ASC defines the role of ASC domains in inflammasome assembly[J]. J Exp Med, 2016, 213( 5): 771- 790. DOI: 10.1084/jem.20151790.
[11]	NAMBAYAN RJT, SANDIN SI, QUINT DA, et al. The inflammasome adapter ASC assembles into filaments with integral participation of its two Death Domains, PYD and CARD[J]. J Biol Chem, 2019, 294( 2): 439- 452. DOI: 10.1074/jbc.RA118.004407.
[12]	MOLLA MD, AYELIGN B, DESSIE G, et al. Caspase-1 as a regulatory molecule of lipid metabolism[J]. Lipids Health Dis, 2020, 19( 1): 34. DOI: 10.1186/s12944-020-01220-y.
[13]	FU JN, WU H. Structural mechanisms of NLRP3 inflammasome assembly and activation[J]. Annu Rev Immunol, 2023, 41: 301- 316. DOI: 10.1146/annurev-immunol-081022-021207.
[14]	BLEVINS HM, XU YM, BIBY S, et al. The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases[J]. Front Aging Neurosci, 2022, 14: 879021. DOI: 10.3389/fnagi.2022.879021.
[15]	BOUCHER D, MONTELEONE M, COLL RC, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity[J]. J Exp Med, 2018, 215( 3): 827- 840. DOI: 10.1084/jem.20172222.
[16]	DUBYAK GR, MILLER BA, PEARLMAN E. Pyroptosis in neutrophils: Multimodal integration of inflammasome and regulated cell death signaling pathways[J]. Immunol Rev, 2023, 314( 1): 229- 249. DOI: 10.1111/imr.13186.
[17]	SWANSON KV, DENG M, TING JPY. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19( 8): 477- 489. DOI: 10.1038/s41577-019-0165-0.
[18]	PELEGRIN P. P2X7 receptor and the NLRP3 inflammasome: Partners in crime[J]. Biochem Pharmacol, 2021, 187: 114385. DOI: 10.1016/j.bcp.2020.114385.
[19]	SHARIF H, WANG L, WANG WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J]. Nature, 2019, 570( 7761): 338- 343. DOI: 10.1038/s41586-019-1295-z.
[20]	BERINGER A, MIOSSEC P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases[J]. Autoimmun Rev, 2018, 17( 12): 1176- 1185. DOI: 10.1016/j.autrev.2018.06.008.
[21]	BUTCHER MJ, ZHU JF. Recent advances in understanding the Th1/Th2 effector choice[J]. Fac Rev, 2021, 10: 30. DOI: 10.12703/r/10-30.
[22]	WU YN, ZHANG R, SONG XC, et al. C6orf120 gene knockout in rats mitigates concanavalin A-induced autoimmune hepatitis via regulating NKT cells[J]. Cell Immunol, 2022, 371: 104467. DOI: 10.1016/j.cellimm.2021.104467.
[23]	LAN PX, FAN YH, ZHAO Y, et al. TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury[J]. J Clin Invest, 2017, 127( 6): 2222- 2234. DOI: 10.1172/JCI91075.
[24]	SMYK DS, MAVROPOULOS A, MIELI-VERGANI G, et al. The role of invariant NKT in autoimmune liver disease: Can vitamin D act as an immunomodulator?[J]. Can J Gastroenterol Hepatol, 2018, 2018: 8197937. DOI: 10.1155/2018/8197937.
[25]	SIRBE C, SIMU GL, SZABO I, et al. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms[J]. Int J Mol Sci, 2021, 22( 24): 13578. DOI: 10.3390/ijms222413578.
[26]	CHRISTEN U, HINTERMANN E. Animal models for autoimmune hepatitis: Are current models good enough?[J]. Front Immunol, 2022, 13: 898615. DOI: 10.3389/fimmu.2022.898615.
[27]	LUAN JY, ZHANG XY, WANG SF, et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated ConA-induced hepatitis[J]. Front Immunol, 2018, 9: 758. DOI: 10.3389/fimmu.2018.00758.
[28]	LIU ZJ, SUN MY, LIU WH, et al. Deficiency of purinergic P2X4 receptor alleviates experimental autoimmune hepatitis in mice[J]. Biochem Pharmacol, 2024, 221: 116033. DOI: 10.1016/j.bcp.2024.116033.
[29]	WANG H, WANG GD, LIANG YJ, et al. Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity[J]. Free Radic Biol Med, 2019, 143: 223- 231. DOI: 10.1016/j.freeradbiomed.2019.08.014.
[30]	WANG H, WANG GD, ANSARI GAS, et al. Trichloroethene metabolite dichloroacetyl chloride induces apoptosis and compromises phagocytosis in Kupffer cells: Activation of inflammasome and MAPKs[J]. PLoS One, 2018, 13( 12): e0210200. DOI: 10.1371/journal.pone.0210200.
[31]	WANG KC, WU WR, JIANG XW, et al. Multi-omics analysis reveals the protection of gasdermin D in concanavalin A-induced autoimmune hepatitis[J]. Microbiol Spectr, 2022, 10( 5): e0171722. DOI: 10.1128/spectrum.01717-22.
[32]	GUAN YL, GU YY, LI H, et al. NLRP3 inflammasome activation mechanism and its role in autoimmune liver disease[J]. Acta Biochim Biophys Sin, 2022, 54( 11): 1577- 1586. DOI: 10.3724/abbs.2022137.
[33]	HUANG Y, XU W, ZHOU RB. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18( 9): 2114- 2127. DOI: 10.1038/s41423-021-00740-6.
[34]	XIE HB, PENG JL, ZHANG XS, et al. Effects of mitochondrial reactive oxygen species-induced NLRP3 inflammasome activation on trichloroethylene-mediated kidney immune injury[J]. Ecotoxicol Environ Saf, 2022, 244: 114067. DOI: 10.1016/j.ecoenv.2022.114067.
[35]	LU FB, CHEN DZ, CHEN L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying microRNA-223-3p[J]. Mol Cells, 2019, 42( 12): 906- 918. DOI: 10.14348/molcells.2019.2283.
[36]	HUANG C, XING X, XIANG XY, et al. MicroRNAs in autoimmune liver diseases: From diagnosis to potential therapeutic targets[J]. Biomed Pharmacother, 2020, 130: 110558. DOI: 10.1016/j.biopha.2020.110558.
[37]	YU YN, DONG H, ZHANG Y, et al. MicroRNA-223 downregulation promotes HBx-induced podocyte pyroptosis by targeting the NLRP3 inflammasome[J]. Arch Virol, 2022, 167( 9): 1841- 1854. DOI: 10.1007/s00705-022-05499-3.
[38]	LA ROSA F, MANCUSO R, AGOSTINI S, et al. Pharmacological and epigenetic regulators of NLRP3 inflammasome activation in Alzheimer’s disease[J]. Pharmaceuticals, 2021, 14( 11): 1187. DOI: 10.3390/ph14111187.
[39]	LIU D, CHENG HL, LUO JF. Exogenous hydrogen sulfide miR-211-5p targeting TLR4 pathway mitigates liver damage in autoimmune hepatitis mice[J]. Immunol J, 2022, 38( 10): 838- 845. DOI: 10.13431/j.cnki.immunol.j.20220117. 刘丹, 程海林, 罗剑锋. MiR-211-5p靶向TLR4通路减轻自身免疫性肝炎小鼠肝损害[J]. 免疫学杂志, 2022, 38( 10): 838- 845. DOI: 10.13431/j.cnki.immunol.j.20220117.
[40]	CHEN L, LU FB, CHEN DZ, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis[J]. Mol Immunol, 2018, 93: 38- 46. DOI: 10.1016/j.molimm.2017.11.008.
[41]	de CARVALHO RIBEIRO M, SZABO G. Role of the inflammasome in liver disease[J]. Annu Rev Pathol, 2022, 17: 345- 365. DOI: 10.1146/annurev-pathmechdis-032521-102529.
[42]	COLL RC, SCHRODER K, PELEGRÍN P. NLRP3 and pyroptosis blockers for treating inflammatory diseases[J]. Trends Pharmacol Sci, 2022, 43( 8): 653- 668. DOI: 10.1016/j.tips.2022.04.003.
[43]	SHI FL, NI ST, LUO SQ, et al. Dimethyl fumarate ameliorates autoimmune hepatitis in mice by blocking NLRP3 inflammasome activation[J]. Int Immunopharmacol, 2022, 108: 108867. DOI: 10.1016/j.intimp.2022.108867.
[44]	SANGINETO M, GRABHERR F, ADOLPH TE, et al. Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease[J]. Liver Int, 2020, 40( 7): 1610- 1619. DOI: 10.1111/liv.14483.
[45]	RAMOS-TOVAR E, MURIEL P. NLRP3 inflammasome in hepatic diseases: A pharmacological target[J]. Biochem Pharmacol, 2023, 217: 115861. DOI: 10.1016/j.bcp.2023.115861.
[46]	LIU GW, ZHAO WX, BAI JM, et al. Formononetin protects against concanavalin-A-induced autoimmune hepatitis in mice through its anti-apoptotic and anti-inflammatory properties[J]. Biochem Cell Biol, 2021, 99( 2): 231- 240. DOI: 10.1139/bcb-2020-0197.
[47]	SILVESTRE GFG, DE LUCENA RP, SILVA ALVES H DA. Cucurbitacins and the immune system: Update in research on anti- inflammatory, antioxidant, and immunomodulatory mechanisms[J]. Curr Med Chem, 2022, 29( 21): 3774- 3789. DOI: 10.2174/0929867329666220107153253.
[48]	MOHAMED GA, IBRAHIM SRM, EL-AGAMY DS, et al. Cucurbitacin E glucoside alleviates concanavalin A-induced hepatitis through enhancing SIRT1/Nrf2/HO-1 and inhibiting NF-‍κB/NLRP3 signaling pathways[J]. J Ethnopharmacol, 2022, 292: 115223. DOI: 10.1016/j.jep.2022.115223.
[49]	LIU QQ, YANG H, KANG X, et al. A synbiotic ameliorates con A-induced autoimmune hepatitis in mice through modulation of gut microbiota and immune imbalance[J]. Mol Nutr Food Res, 2023, 67( 7): e2200428. DOI: 10.1002/mnfr.202200428.
[50]	KANG YB, KUANG XY, YAN H, et al. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4/NF-κB/NLRP3 signaling pathway[J]. mSystems, 2023, 8( 2): e0112722. DOI: 10.1128/msystems.01127-22.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (125) PDF downloads(14)

Research advances in the mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in autoimmune hepatitis

DOI: 10.12449/JCH241027

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in the mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in autoimmune hepatitis

DOI: 10.12449/JCH241027

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content